1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazi-2-yl)ureas as potent and selective inhibitors of Chk1 kinase: Synthesis, preliminary SAR, and biological activities

Journal of Medicinal Chemistry

Volumn 48, Issue 9, 2005, Pages 3118-3121

  Wang, Gary T ^a   Li, Gaoquan ^a   Mantei, Robert A ^a   Chen, Zehan ^a   Kovar, Peter ^a   Gu, Wendy ^a   Xiao, Zhan ^a   Zhang, Haiying ^a   Sham, Hing L ^a   Sowin, Thomas ^a   Rosenberg, Saul H ^a   Lin, Nan Horng ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 CHLORO 2 PHENYL) 3 (5 CYANOPYRAZIN 2 YL)UREA DERIVATIVE; 7 HYDROXYSTAUROSPORINE; CAMPTOTHECIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 1 INHIBITOR; CHECKPOINT KINASE 2; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN KINASE C DELTA; PROTEIN KINASE C GAMMA; PROTEIN KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CHEMOSENSITIVITY; DEPHOSPHORYLATION; DNA DAMAGE; DNA SYNTHESIS INHIBITION; DRUG ACTIVITY; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HELA CELL; HUMAN; HUMAN CELL; IC 50; IONIZING RADIATION; MITSUNOBU REACTION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL CYCLE; CRYSTALLOGRAPHY, X-RAY; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; NITRILES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRAZOLES; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 20944439528     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm048989d     Document Type: Article

References (25)

1. Reviews: (a) Zhou, B. B.; Bartek, J. Targeting the checkpoint kinases: Chemosensitization versus chemoprotection. Nat. Rev. Cancer 2004, 4, 1-10.
2. (b) Kong, N.; Fotouhi, N.; Wovkulich, Roberts, J. Cell cycle inhibitors for treatment of cancer. Drugs Future 2003, 28, 881-896.
3. Draette, G.; Eckstein, J. Cdc25 protein phosphatases in cell proliferation. Biochim. Biophys. Acta 1997, 1332, M53-63.
4. Lee, M.-H.; Yang, H.-Y. Regulators of G1 cyclin-dependent kinases and cancers. Cancer Metastasis Rev. 2003, 3, 305-307.
5. Abraham, R. T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Develop. 2001, 15, 2177-2196.
6. Xiao, Z.; Chen, Z.; Gunasekera, A.; Sowin, T. H.; Rosenberg, S. H.; Fesik, S.; Zhang, H. Chk1 mediated S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J. Biol. Chem. 2003, 278, 21767-21773.
7. Zhao, H.; Watkins, J. L.; Piwnica-Worms, H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc. Natl. Acad. Sci. 2002, 99, 14795-14800.
8. Sorensen, C. S.; Syljuasen, R. G.; Falck, J.; Schroeder, T.; Ronnstrand, L.; Khanna, K. K.; Zhou, B. B.; Lukas, J. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 2003, 3, 247-258.
9. Cliby, W. A.; Lewis, K. A.; Lilly, K. K.; Kaufmann, H. S Phase and G2 phase arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J. Biol. Chem. 2002, 277, 1599-1606.
10. -/- mice. Genes Dev. 2000, 14, 1439-1447.
11. Liu, Q.; Guntuku, S.; Cui, X.; Matsuoka, S.; Cortez, D.; Tamai, K.; Carattini-Rivera, S.; DeMayo, F.; Bradley, A.; Donehower, L. A.; Elledge, S. J. Chk1 is an essential kinase that is regulated by ATR and required for the G2/M DNA damage checkpoint. Genes Dev. 2000, 14, 1448-1459.
12. Hirose, Y.; Berger, M. S.; Pieper, R. O. Abrogation of the Chk1-mediated G2 checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 2001, 61, 5843-5849.
13. Powell, S. N.; DeFrank, J. S.; Connell, P.; Eogan, M.; Preffer, F.; Domkowski, D.; Tang, W.; Friend, S.; Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res. 1995, 55, 1643-1648.
14. Kawabe, T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 2004, 3, 513-519.
15. Koniaras, K.; Cluddihy, A. R.; Christopoulos, H.; Hogg, A. O'Connell, M. J. Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene, 2001, 20, 7453-7463.
16. Wang, H.; Wang, X.; Zhou, X.-Y.; Chen, D. J.; Li, G. C.; Iliakis, G.; Wang, Y. Ku Affects Ataxia and Rad 3-raleated/Chk1-dependent S phase checkpoint response after camptothecin treatment. Cancer Res. 2002, 62, 2483-2487.
17. Chen, Z.; Xiao, Z.; Chen, J.; Ng, S. C.; Sowin, T.; Sham, H. L.; Rosenberg, S. H.; Fesik, S.; Zhang, H. Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol. Cancer Ther. 2003, 2, 543-548.
18. Zhao, B.; Bower, M.; McDevitt, Zhao, H.; Davis, S. T.; Johanson, K. O.; Green, S. M.; Concha, N. O.; Zhou, B. Structure basis for Chk1 inhibition by UCN-01. J. Biol. Chem. 2002, 48, 46609-46615.
19. Graves, P. R.; Yu, L.; Schwarz, J. K.; Gales, J.; Sausville, E. A.; O'Connor, P. M.; Piwnica-Worms, H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 2000, 275, 5600-5605.
20. Li, G.; Li, Q.; Li, T.; Lin, N.-H.; Mantei, R. A.; Sham, H. L.; Wang, G. T. Preparation of urea kinase inhibitors. US 2004034038, 2004.
21. Keegan, K.; Kesicki, E. A.; Gaudino, J. J.; Cook, A. W.; Cowen, S. D.; Gurgess, L. E. Aryl and heteroaryl urea Chk1 inhibitors for use as radiosensitizers and chemosensitizers. WO 02/070494, 2002.
22. Boyle, R. G.; Imogai, H. J.; Cherry, M. Diaryl urea compounds and derivatives as Chk1 inhibitors for the treatment of cancer. WO 03/101444, 2003.
23. Wang, G. T.; Li, G.; Mantei, R. A.; Lin, N.-H.; Xia, P.; Hasvold, L.; Gwaltney, S.; Li, Q.; Li, T.; Park, C.; Chen, Z.; Kovar, P.; Gu, W.; Xiao, Z.; Zhang, H.; Luo, Y.; Giranda, V.; Sham, H. L.; Sowin, T.; Rosenberg, S. H. J. Med. Chem., in press.
24. Wang, G. T.; Li, G.; Mantei, R. A.; Lin, N.-H.; Park, C.; Chen, Z.; Kovar, P.; Gu, W.; Xiao, Z.; Zhang, H.; Sham, H. L.; Sowin, T.; Rosenberg, S. H. J. Med. Chem. in press.
25. Chen, Z.; Xiao, Z.; Gu, W.; Bui, M. H.; Merta, P. J.; Wang, G. T.; Li, G.; Lin, N. H.; Kovar, P.; Sham, H. L.; Rosenberg, S. H.; Sowin, T. J.; and Zhang, H. A-641397, a highly selective Chk1 inhibitor augments DNA damaging agents against human cancer cells. Manuscript in preparation.